{"symbol":"AMGN","provider":"yahoo-finance","fetchedAt":"2025-12-22T21:55:59.188Z","asOfDate":"2025-12-22","articles":[{"id":"65a995e2-731e-3bd8-ac46-a5c62b2ff7d7","title":"SCHD vs. NOBL: Different Paths to Dividend Stability","url":"https://finance.yahoo.com/m/65a995e2-731e-3bd8-ac46-a5c62b2ff7d7/schd-vs.-nobl%3A-different.html","publisher":"Motley Fool","publishedAt":"2025-12-22T21:31:52.000Z","relatedTickers":["SCHD"],"mainIdea":"SCHD vs. NOBL: Different Paths to Dividend Stability","summary":"Motley Fool: SCHD vs. NOBL: Different Paths to Dividend Stability. Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency Related tickers mentioned: SCHD."},{"id":"9ecc3ce3-9c26-3064-a686-e56ae6206c94","title":"Celldex Therapeutics Stock Gets RS Rating Lift","url":"https://finance.yahoo.com/m/9ecc3ce3-9c26-3064-a686-e56ae6206c94/celldex-therapeutics-stock.html","publisher":"Investor's Business Daily","publishedAt":"2025-12-22T20:42:10.000Z","relatedTickers":["CLDX"],"mainIdea":"Celldex Therapeutics Stock Gets RS Rating Lift","summary":"Investor's Business Daily: Celldex Therapeutics Stock Gets RS Rating Lift. A Relative Strength Rating upgrade for Celldex Therapeutics shows improving technical performance. Will it continue? Related tickers mentioned: CLDX."},{"id":"d2a21e3e-9434-3383-b6f5-60a8f6036507","title":"Analyst Report: Amgen Inc.","url":"https://finance.yahoo.com/m/d2a21e3e-9434-3383-b6f5-60a8f6036507/analyst-report%3A-amgen-inc..html","publisher":"Morningstar Research","publishedAt":"2025-12-22T16:33:41.000Z","relatedTickers":[],"mainIdea":"Analyst Report: Amgen Inc.","summary":"Morningstar Research: Analyst Report: Amgen Inc.. Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm"}]}
